[Hematopoietic growth factors in the treatment of malignant hemopathies].
The authors analyze the role of G-CSF and GM-CSF in hematological malignancies. These allow correction of drug-induced neutropenias and perhaps more importantly allow the increase of doses of chemotherapy to improve the antitumor effect, and permit the maintenance of full chemotherapy doses in elderly patients. They can also mobilize peripheral blood stem cells for autologous and recent allogeneic transplantation. They can be useful at low doses in correcting the spontaneous neutropenia of bone marrow failures. A specific antitumor effect, on the other hand, is extremely hypothetical. Erythropoietin by contrast has been disappointing in the treatment of anemia in spontaneous bone marrow failures. For the treatment of thrombocytopenias, preliminary results with thrombopoietin are encouraging. Combinations of growth factors will probably improve results obtained with one factor. However, in all cases the cost/benefit of growth factors will have to be strictly established.
Fenaux
P
P
Service des maladies du sang, hôpital Claude-Huriez, Lille, France.
D019337:Hematologic Neoplasms / Q000191:economics / Q000628:therapy*; D016298:Hematopoietic Cell Growth Factors / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000191:economics / Q000628:therapy; D011788:Quality of Life
D016298:Hematopoietic Cell Growth Factors